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Review Article
Perioperative Management of Pheochromocytoma: Anaesthetic Implications
Aliya Ahmed
Department of Anaesthesia, Aga Khan University Hospital, Karachi.
Abstract
Pheochromocytoma is a catecholamine producing
tumour that can cause severe hypertension and other sys-
temic disturbances. The perioperative management of
pheochromocytoma remains a complicated anaesthesia
challenge requiring intensive preoperative preparation and
vigilant intraoperative and postoperative care. In this article
the perioperative management of pheochromocytoma is
reviewed by first summarizing its pathophysiology, clinical
aspects and diagnosis, then highlighting the preoperative
optimization of the patient and finally describing the intra-
operative and postoperative anaesthetic management in the
light of the current information.
Introduction
Pheochromocytoma is a catecholamine secreting
tumour that arises from the chromaffin cells of the sympa-
thetic nervous system in the adrenal medulla and the sym-
pathetic chain; however, it may arise anywhere in the body.1
Patients present with a variety of symptoms which reflect
excessive secretion of catecholamines (norepinephrine, epi-
nephrine, or dopamine) into the circulation.2 The released
catecholamines cause significant hypertension, often severe
and refractory to conventional treatment.1-5
Early diagnosis and definitive treatment with surgi-
cal resection is important because the tumour may be fatal
if undiagnosed, especially in patients undergoing surgery
for other disorders or in pregnant women during delivery.1,4
Despite recent developments in technology, monitoring and
pharmacology, perioperative management of pheochromo-
cytoma remains a highly stressful situation for the anaesthe-
siologists.5 Appropriate preoperative medical management
dramatically decreases morbidity and mortality during the
operative management of this tumour.6 This article reviews
the perioperative management of pheochromocytoma by
first summarizing its pathophysiology, clinical aspects and
diagnosis, then highlighting the preoperative optimization
of the patient and finally describing the intraoperative and
postoperative anaesthetic management.   
Pathophysiology
Pheochromocytomas arise in the chromaffin cells of
neuroectodermal origin. During embryonic development
the chromaffin cells settle mainly near the sympathetic gan-
glia, vagus nerve, paraganglia and carotid arteries but some
chromaffin tissue may be present in the bladder wall,
prostate, rectum, gonads, renal and hepatic hili.7 Thus
pheochromocytomas can arise at any of these sites.1 An
understanding of biochemistry and functions of cate-
cholamines is important for appreciating the pathophysiolo-
gy of pheochromocytomas. The biosynthesis and metabo-
lism of catecholamines is illustrated in Figure.
The actions of catecholamines are mediated by the
alpha adrenergic and the beta adrenergic receptors.8 Alpha 1
receptors cause vascular constriction while alpha 2 recep-
tors mediate the presynaptic feedback inhibition of norepi-
nephrine release and decrease insulin secretion. Beta 1
receptors increase cardiac rate and contractility and beta 2
receptors lead to arteriolar and venous dilation and relax-
ation of tracheobronchial smooth muscle.1,8
The symptoms caused by pheochromocytoma are
due to the effects of a large amount of catecholamines, nor-
epinephrine and epinephrine in the circulation.5 Most
pheochromocytomas (more than 80%) mainly secrete nor-
epinephrine, sometimes paroxysmally, but usually sus-
tained.3 In rare cases, these tumours may produce epineph-
rine predominantly.1 Some tumours may secrete dopamine
and various peptides and ectopic hormones.9 Increased
dopamine secretion by a pheochromocytoma may suggest
malignancy.10
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Clinical Aspects
Pheochromocytoma is a rare tumour with a reported
incidence in the United States of 1.55 to 2.1 per million pop-
ulations per year.11 This tumour is also rare in the Pakistani
population but its actual incidence is not yet reported. The
greatest frequency occurs in the fourth and fifth decade of
life, with a slightly higher female preponderance.3 About
90% of pheochromocytomas occur sporadically and are
benign.12 In 10% of patients with pheochromocytoma, the
adrenal tumour is part of a familial disorder such as the mul-
tiple endocrine neoplasia (MEN) syndrome, von
Recklinghausen disease or von Hippel-Lindau syndrome.13
Around 10% of cases occur in children or adolescents.1
Hypertension is the commonest presenting sign in
patients with pheochromocytoma as most of these tumours
secrete predominantly norepinephrine.4,14,15 The classical
symptoms are headaches, palpitations and episodic sweat-
ing.4,5 Central nervous system manifestations are anxiety,
nervousness, psychosis, visual disturbance and tremors.
Cardiovascular symptoms include ventricular arrhythmias,
cardiac failure with cardiomyopathy, and peripheral vaso-
constriction with pallor.3 Acute pulmonary oedema may
complicate pheochromocytoma at any time.16 Prolonged
exposure of the circulation to high norepinephrine concen-
trations results in constriction of both arteriolar and venous
circulation with a marked decrease in circulating blood vol-
ume.2,5
Some patients present with increased blood glucose
concentrations as a result of glycogenolysis and impaired
insulin release by the islet cells of pancreas.2,17 The author
was involved in the anaesthetic management of a patient
who presented with severe uncontrolled diabetes mellitus
and no history of hypertension. On abdominal computerized
tomography (CT) he was found to have a right adrenal
mass. The opinion of an endocrinologist was not in favour
of a pheochromocytoma as none of the classical signs or
symptoms were present. However, anaesthetic management
for the resection of the mass was performed with full pre-
cautions as for a pheochromocytoma. The histopathological
examination of the resected mass proved it to be one. The
patient's glycaemic level normalized after removal of the
tumour. 
A small proportion of patients with pheochromocy-
toma present with paroxysmal symptoms which reflect
excessive secretion of epinephrine and dopamine.1
Excessive epinephrine secretion causes hypermetabolism
with weight loss, paroxysmal tachycardia, palpitations,
sweating and stimulation of insulin release through a beta 2
adrenoceptor mechanism.16 The overall picture depends
upon the relative proportions of norepinephrine and epi-
nephrine secreted by the tumour. Pheochromocytoma is an
extremely rare tumour in children18 but should be searched
for in children presenting with hypertension and especially
those with family history of MEN syndromes.  
Diagnosis
At the first presentation, the hypertension might not
warn the treating physician about pheochromocytoma, but
hypertension resistant to conventional treatment along with
intermittent severe headache and palpitations should alert
the physician about the presence of a pheochromocytoma.
Once there is a suspicion, the best confirmatory test is to
measure free catecholamines and their metabolites in a 24
hour urine collection.3,5 These measurements include epi-
nephrine, norepinephrine, dopamine, metanephrine, and
vanillylmandellic acid (VMA). Measurement of plasma cat-
echolamines reflect only that single moment when the blood
sample was collected. Twenty four hours urinary VMA is
the only biochemical test currently available for confirming
the diagnosis of pheochromocytoma.  
Figure. Biosynthesis and metabolism of catecholamines.
Table. Intraoperative Considerations.
An anxiolytic should be given preoperatively
Arterial catheter should be placed before induction
Intravenous catheter for antihypertensive and fluid administration
should be placed before induction
Epidural (optional) to be placed before induction
Central venous catheter should be placed for intravascular volume 
monitoring
Haemodynamic fluctuations should be treated with antihypertensives and 
adrenergic antagonists
Hypotension and hypoglycemia should be monitored after tumor isolation
Phenylalanine
Tyrosine
DOPA
DOPAMINE
NOREPINEPHRINE EPINEPHRINE
Normetanephrine Vanillylmandellic Metanephrine
Acid
141 J Pak Med Assoc
VMA is the only biochemical test currently available
for confirming the diagnosis of pheochromocytoma.  
Once the diagnosis has been established, the tumour
must be localized to facilitate its surgical removal. Although
larger tumours may be located with ultrasonography, most
tumours require CT scanning or magnetic resonance imag-
ing (MRI) especially when located outside the adrenal
gland.1 CT and MRI both provide an accurate identification
of the majority of pheochromocytomas.19 Tumours in
unusual sites and metastases may have to be identified with
metaiodobenzylguanidine (MIBG) scintigraphy, which has
a high specificity for pheochromocytoma as MIBG is con-
centrated by the tumour's avid uptake of precursor amines.2
Preoperative Assessment 
Surgical resection of the tumour is the only curative
procedure. Prior to surgery it is imperative to control arteri-
al pressure, heart rate and arrhythmias and to restore the
blood volume to normal.1-5,14,15,17 The anaesthesiologist
should take relevant history, assess the severity of hyperten-
sion and look for any end-organ damage, especially cate-
cholamine induced cardiomyopathy and cardiac failure,
which is associated with a high mortality.3,20
For a detailed assessment of cardiovascular status
electrocardiography (ECG), chest X-ray and M-mode
echocardiography should be advised. ECG might show
hypertrophy, arrhythmias, cardiomyopathy, ischaemia or
infarction. Chest X-ray may reveal cardiomegaly or pul-
monary oedema.5 M-mode echocardiography should be
used to assess left ventricular dysfunction, evaluate
improvement after alpha adrenergic blockade, and deter-
mine the optimal timing of surgery.5, 21
A baseline full blood count and haematocrit fol-
lowed by serial monitoring provides an assessment of the
adequacy of volume expansion when alpha adrenergic
blockade has been started.17 An assessment of renal func-
tion should be carried out by biochemical investigations
such as urea, creatinine and electrolytes. Insulin therapy
may be required if hyperglycaemia is present. If hypercal-
caemia is present, the presence of MEN type 11 should be
suspected.3
Preoperative Management
Adrenergic crisis leading to an uncontrollable situa-
tion may occur at induction of anaesthesia, intubation, and
during tumour handling.1 Appropriate preoperative medical
management dramatically decreases morbidity and mortali-
ty during the operative management of pheochromocy-
toma.6 Therefore it is important to adequately optimize the
patient before surgery. There has been a decrease in mortal-
ity associated with its resection from 40-60% to 0-6% over
the last 50 years.22 There should be close cooperation
between the cardiologist, endocrinologist, surgeon and the
anaesthesiologist for an uneventful outcome.
Preoperative preparation is conventionally done with
alpha adrenergic blockade over a period of 10-14 days and
subsequently, additional beta adrenergic blockade is
required to treat any associated tachyarrhythmias.5 Patients
can usually be safely prepared for surgery on an outpatient
basis. Alpha blockade is commonly achieved with oral phe-
noxybenzamine 20mg three times daily, which is a non
competitive, non-selective alpha adrenergic blocking
agent.23 It also permits spontaneous volume expansion but
this occurs gradually and takes two to three weeks. Half-life
of phenoxybenzamine is more than 24 hours. Noninvasive
blood pressure monitoring should be done in the supine and
standing positions during therapy.24
Selective competitive alpha 1 adrenergic antagonists
are preferred by some anaesthesiologists because they do
not produce reflex tachycardia, have a shorter duration of
action, can be adjusted rapidly before surgery and the dura-
tion of postoperative hypotension is decreased.23 Prys-
Roberts used doxazosin preoperatively in 20 patients with
pheochromocytoma or paraganglioma in doses of 2 to 8mg
daily and noted that preoperative blood pressure was con-
trolled as well as with phenoxybenzamine.2
Other selective competitive alpha 1 adrenergic
antagonist like prazosin can also be used. It has a short elim-
ination half life of two to three hours and requires more fre-
quent dosing5 starting at 1mg three to four times daily and
gradually increased up to 12mg daily.17,23 Its blood concen-
tration may decrease to ineffective levels at the time of sur-
gery if the last dose was given on the night before surgery.24
Terazosin is a similar alternative selective alpha 1 adrener-
gic antagonist. The choice of drug will depend not only on
the physician's preference but also upon availability and
cost effectiveness. Whichever drug is used, it is important to
introduce it cautiously starting with small doses and
increasing gradually until orthostatic hypotension develops
indicating adequate alpha blockade.3 Despite preoperative
alpha blockade, significant increases in blood pressure still
occur intraoperatively, especially during tumour manipula-
tion.24
During alpha receptor blockade tachycardia and
arrhythmias can occur due to resultant unopposed beta
receptor activity.1,8 The tachycardia and arrhythmias are
controlled by carefully introducing beta adrenergic block-
ers. Beta blockade should never be instituted until alpha
adrenergic blockade is fully established as unopposed alpha
stimulation may lead to severe hypertension.23 
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Caution is also required in patients with cardiomyopathy
who may develop pulmonary oedema due to withdrawal of
beta stimulation.25 Thus, beta adrenergic blockade should
be avoided in patients with catecholamine induced car-
diomyopathy as it can lead to development of intractable
hypotension, bradycardia and asystolic arrest.5,26 Selective
beta I adrenoceptor antagonists such as atenolol (100 mg
day-1) or bisoprolol (10-20 mg day-1) should be used in
order to minimize undesirable side effects in the bronchi or
peripheral vasculature.2 Non-selective beta 1 antagonists
such as propranolol (40-240 mg day-1) or metoprolol (50-
200 mg day-1) can also be used3 but care must be taken in
patients with history of obstructive airway disease or
peripheral vascular disease. Calcium channel blockers (27)
have also been employed in the preoperative and intraoper-
ative haemodynamic control, such as nifedipine 30-90 mg
day-1 and nicardipine infusion starting at 5 mg hour-1,
increasing by 2.5 mg hour-1 every 5 minutes to a maximum
of 15 mg hour-1. 
Preoperative sedation and anxiolysis, preferably
with a benzodiazepine, and assurance by the anaesthesiolo-
gist will decrease anxiety and prevent marked haemody-
namic fluctuation in the immediate preoperative period.5
Patients often develop hypertensive swings during surgical
manipulation of the tumour despite complete pharmacolog-
ical blockade. Therefore medication for alpha and beta
blockade should be continued until the day of the operation
except phenoxybenzamine which may be stopped the day
before surgery as it has a long half life and can cause post-
operative hypotension.2
Intraoperative Management 
Close communication between the surgeon and the
anaesthesiologist is absolutely crucial to the success of
intraoperative management of patients undergoing resection
of pheochromocytoma. Preoperative discussion of antici-
pated problems is important and guides the anaesthesiolo-
gist in making adequate preparation for the anaesthetic
management.
Various anaesthetic techniques have been success-
fully employed for the resection of pheochromocy-
toma.2,3,5,17 Regional anaesthesia has been used alone or in
combination with general anaesthesia and neurolept tech-
nique.28 The choice of anaesthesia does not influence the
outcome of the operation.3 and a rational anaesthetic tech-
nique based on sound pharmacologic principles should be
selected. Based on 32 years of experience with this surgery,
Prys-Roberts has suggested a practical rational anaesthesia
technique consisting of a mid to low thoracic epidural com-
bined with adequate general anaesthesia and selective
adrenergic antagonists to control haemodynamic surges in
response to tumour manipulation.2 Many drugs have been
suggested for the control of intraoperative haemodynamic
surges1-3,5,17, but the choice of drugs used for this purpose,
especially in the developing world, will depend upon the
availability of the drugs in addition to patient's require-
ments.    
Anaesthetic Management
Perioperative management of pheochromocytoma
remains an anaesthetic challenge even in the best of cen-
ters29 and involvement of experienced surgeon and anaes-
thesiologist is mandatory. The patient should be transferred
cautiously to the operating table to avoid any straining
which may cause catecholamine release.3 After connecting
ECG and pulse oximeter and assessing blood pressure non-
invasively, central venous and arterial catheters should be
placed under local anaesthesia to establish haemodynamic
monitoring. This could be easily achieved with a gentle
technique and reassurance of the patient and allows imme-
diate identification of haemodynamic fluctuations during
induction and maintenance of anaesthesia and surgical
manipulation of the tumour, and also guides for pharmaco-
logic intervention.5 If the patient is nervous the central
venous catheter could be placed immediately after induc-
tion. Pulmonary artery catheter is not an absolute require-
ment and should be reserved for patients with severe left
ventricular dysfunction and preoperative cardiovascular
compromise.30 Routine monitoring should include ECG,
capnography, inspired oxygen concentration (FiO2), pulse
oximetry, neuromuscular blockade, temperature and urine
output.17
Preferably two large bore intravenous catheters should
be placed, one of them before induction under local anaesthe-
sia, for administration of medications and fluids. The patient
can then be positioned gently for insertion of the epidural
catheter at the T10-11 to T12-L1 level.2 In the author's insti-
tute it is a common practice to insert the epidural catheter
before the induction of anaesthesia. The epidural could be
used for both intraoperative and postoperative analgesia or an
intravenous opioid agent like fentanyl can be used intraopera-
tively and an epidural bolus followed by continuous infusion
can be used for postoperative analgesia. 
Although various anaesthetic drugs and techniques
have been used for this purpose, the author, after review of
literature2-6,17,31 has endeavored to describe a practical and
safe approach for the induction and maintenance of anaes-
thesia for pheochromocytoma resection in the following
section. This technique is equally applicable for both open
and laparoscopic surgical approaches. 
After initiation of monitoring and preoxygenation
anaesthesia is induced with fentanyl 2-5 mcg kg-1 and
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propofol 1-2 mg kg-1. Thiopentone has been widely used
without adverse effects31 but can cause histamine release,
which need to be avoided in these patients.3 Etomidate pro-
vides cardiovascular stability but causes pain on injection
and involuntary movements which are undesirable.
Midazolam could be used to facilitate co-induction.3 Other
opioids like alfentanil or sufentanil could also be used in
place of fentanyl. Remifentanil infusion has also been used
and has shown good results31 and could be considered if
availability and cost permits. 
When the patient no longer responds to commands
neuromuscular blocking agent is administered.
Suxamethonium has been used successfully for rapid
sequence induction in a pregnant patient with pheochromo-
cytoma undergoing caesarean section under general anaes-
thesia31, but it should be best avoided as the muscular fasci-
culation may mechanically squeeze the tumour. Atracurium
and mivacurium have been shown to release histamine, but
Prys-Roberts2 has used atracurium regularly for patients
with pheochromocytoma since 1984 without any unfavor-
able effects. Vecuronium, rucuronium and cisatracurium
have shown cardiovascular stability and release the least
histamine and appear to be suitable agents for this purpose.
After administering neuromuscular blocking agent, the
lungs are manually ventilated with isoflurane 1-2% in oxy-
gen for 3-5 minutes followed by tracheal intubation. The
patient's lungs are ventilated through a nasogastric tube with
a tidal volume of 7-10 ml kg-1 and a rate of 10-12
breaths/min-1 to maintain the end tidal CO2 (PETCO2)
around 35 mmHg. The patient is then cautiously positioned
for the planned surgical approach.
Anaesthesia is maintained with isoflurane 1-2% in
an air-oxygen mixture with FiO2 of around 0.5. Isoflurane
is preferred because, unlike halothane, it does not sensitize
the myocardium to catecholamines.17 Sevoflurane has also
been used successfully.32 and can be used depending upon
its availability and economic issues. Its rapid uptake and
elimination allows easier control of depth of anaesthesia
and haemodynamics of the patient.32 Nitrous oxide is also
not contraindicated and could be added if preferred. Boluses
or infusion of neuromuscular blocking drug are used to
maintain good surgical conditions. 
If epidural infusion is being used intraoperatively,
further doses of fentanyl or any other opioid are usually not
required. To achieve adequate intraoperative and postopera-
tive analgesia with the epidural, infusion of bupivacaine
0.1-0.125% with fentanyl 2 mcg ml-1 at the rate of 6-12 ml
hour-1, is administered after an initial bolus of 8-10 ml of
0.25% bupivacaine in divided doses.2,5
For reversal of neuromuscular blockade, a combina-
tion of neostigmine and glycopyrrolate is used, as the tachy-
cardia associated with atropine can lead to a hypertensive
spike.3 The decision to reverse neuromuscular blockade at
the end of surgery or electively ventilating the patient in
ICU until stability is achieved depends upon the preopera-
tive state of the patient and the intraoperative course. Even
if the trachea is successfully extubated at the end of surgery,
the patient is kept in the ICU or high dependency unit at
least for the first twenty four hours and closely monitored
for haemodynamic instability.2-6,17,31 . 
Control of perioperative catecholamine release
As mentioned above, manipulation of the tumour
causes a significant haemodynamic response and both sys-
tolic and diastolic blood pressures increase briskly. Sodium
nitroprusside (SNP), phentolamine, prazosin, nitroglycerine
and various other agents like magnesium sulphate, nicardip-
ine, diltiazem, esmolol etc, have been used to control intra-
operative rises in blood pressure.2,5,6,14,15,17 In the author's
institute sodium nitroprusside is preferred for this purpose. It
is a potent arterio-venodilator with a rapid and brief action
and is used as a titratable intravenous infusion [around 0.5
mcg kg-1 min-1].17 With the small quantity used,  cyanide
toxicity is not a problem. Intravenous nitroglycerine can also
be employed for this purpose. It is a rapid acting agent that
mainly affects capacitance vessels.30 Similar to SNP, its
onset and duration are rapid.5 The competitive alpha adren-
ergic blocking agent phentolamine can also be used intraop-
eratively as an infusion or in incremental doses of 1 to 2 mg
to control acute hypertensive crises because it acts fast and
has a short half-life.3 It is associated with tachycardia but in
patients receiving beta adrenergic antagonists, tachycardia
attributable to phentolamine is not typically seen.2
Intraoperative use of beta adrenergic antagonists can
help control tachycardia and tachyarrhythmias. Esmolol has
haemodynamic effects that may be uniquely suited for the
intraoperative management of pheochromocytoma.33 Its
rapid effect and short duration makes it easily titratable,
both to control heart rate and blood pressure. The author has
used metoprolol 1-2 mg IV boluses intraoperatively with
good results.
Magnesium sulphate inhibits catecholamine release
from chromaffin cells and alters the adrenergic receptors
response.34 James describes a series of 17 patients in whom
intraoperative haemodynamic control was achieved with a
loading dose of 40 - 60 mg kg-1 followed by an infusion of
1-2 g h-1.34 Additional doses of magnesium sulphate were
required in all patients at the time of tumor manipulation.
Calcium channel blockers e.g. nifedipine and nicardipine
have also been used for intraoperative haemodynamic con-
trol.27
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It is difficult to comment on the best medication to
be used for haemodynamic control during resection of
pheochromocytoma as it is not possible to conduct properly
designed randomized trials because of the rarity of the con-
dition. It has been suggested17 for the anesthesiologists to
rely on their familiarity of particular drugs or methods. In a
developing country, the availability and affordability also
becomes an issue of major consideration.
Postoperative Management
After the adrenal veins are ligated, there is a sudden
decrease in the circulating catecholamines which may lead
to hypotension. At this point the vasodilators and   blocker
should be discontinued and a modest fluid bolus should be
given. An eye must be kept on the blood loss and blood
given if required. Infusion of a vasopressor such as norepi-
nephrine or phenylephrine may be required temporarily.5
The three most important complications in the
immediate postoperative period are hypertension, hypoten-
sion and hypoglycaemia.3 Approximately 50% of patients
remain hypertensive for a few days, most likely related to
elevated catecholamine levels which may persist for one
week after pheochromocytoma resection.30 Therefore
restarting or continuation of antihypertensive medication
may be required for a few days. Presence of residual tumour
must be considered in cases of persistent hypertension and
catecholamine levels should be repeated. Persistent
hypotension may be due to residual effects of preoperative
adrenergic blockade.17 There should also be a high index of
suspicion for intra-abdominal bleeding. 
After removal of the tumour the pancreatic beta cell
suppression is no longer present and insulin levels increase.
The lipolysis and glycogenolysis is also absent due to
removal of tumour and alpha blockade.17 This may lead to
hypoglycaemia which may be associated with encephalopa-
thy and the residual adrenergic blockade may mask its signs
and symptoms.35 Therefore blood glucose levels should be
monitored in the perioperative period and glucose contain-
ing intravenous fluids should be started after tumour
removal.6
Conclusion
The anaesthetic management of patients with
pheochromocytoma remains a challenge to even the most
experienced of anaesthesiologist, although the perioperative
mortality has reduced remarkably. Surgical resection is the
definitive treatment. Preoperative control of hypertension
with alpha adrenergic blocking agents followed, where
required, by beta adrenergic blocking drugs and adequate
volume expansion is important for reducing the morbidity
and mortality associated with this surgery. Patients with
pheochromocytoma should ideally be managed by an expe-
rienced team of endocrinologist, endocrine surgeon and
anaesthesiologists. Different anaesthetic techniques and
medications have been used successfully and various com-
binations of vasodilating and antihypertensive drugs have
been used intraoperatively during the resection of pheochro-
mocytoma with good results. The pathophysiology of the
disease is complex and anaesthetic care must be tailored in
accordance with each patient's situation. 
References
1. Vuguin P, Perez N, Monsalve MM. Pheochromocytoma. Web article from
eMedicine Specialties>Pediatrics>Oncology. Last updated: June 5, 2006.
eMedicine from WebMD. www.emedicine.com/ped/topic1788.htm 
2. Prys-Roberts C. Pheochromocytoma - recent progress in its management. Br
J Anaesth 2000; 85:44-57.
3. Singh G, Kam P. An overview of anaesthetic issues in Pheochromocytoma.
Ann Acad Med Singapore 1998; 27:843-8.
4. Kariya N, Nishi S, Hosono Y, Hamaoka N, Nishikawa K, Asada A. Cesarean
section at 28 weeks' gestation with resection of pheochromocytoma: periop-
ertive antihypertensive management. J Clin Anesth 2005; 17:296-9.
5. Kinney MA, Narr BJ, Warner MA. Perioperative Management of
Pheochromocytoma. J Cardiothorasc Vasc Anesth 2002; 16:359-69.
6. Schif RL, Welsh GA. Perioperative evaluation and management of the patient
with endocrine dysfunction. Med Clin N Am 2003; 87:175-92.
7. Greenspan FS, Forsham PH, eds: Pheochromocytoma. In: Basic and clinical
endocrinology. 2nd ed. New York, NY: McGraw Hill !986; pp. 336-44.
8. Catecholamines as Neurotransmitters/Hormones. © 1996-2004 University of
Washington. http://courses.washington.edu/chat543/cvans/sfp/catechol.html
9. Bouloux PM. Multiple endocrine neoplasia. Surgery 1987; 1:1180-5.
10. Araki S, Kato M, Kase H, Okada K. Hyperdopaminemia may produce an
increased outlet resistance of the prostatic urethra: a case report of malignant
pheochromocytoma. J Urol 1995;153:1614-5 [Abstract].
11. Greene JP. New perspectives in pheochromocytoma. Urol Clin North Am
1989;16:487-503.
12. Manger WM, Gifford JW Jr. Phaeochromocytoma: a clinical overview. In:
Swales JD ed. Textbook of Hypertension. Oxford: Blackwell Scientific 1994;
pp. 941-58
13. Mihai R, Farndon JR Familial endocrine disease - genetics and early treat-
ment. In: Farndon JR, ed. A companion to specialist surgical practice, Vol 5:
Breast and Endocrine Surgery. London: W. B. Saunders 1997; pp. 113-42.
14. Tauzin-Fin P, Sesay M, Gosse P, Ballanger P. Effects of perioeprative alphal
block on haemodynamic control during laparoscopic surgery for phaeochro-
mocytoma. Br J Anaesth 2004; 92:512-7.
15. Chung PC, Ng YT, Hsieh JR, Yang MW, Li AH. Labetalol pretreatment
reduces blood pressure instability during surgical resection of pheochromocy-
toma. J Formos Med Assoc 2006;105:189-93.
16. Fahmy N, Assad M, Bathijad P, Whittier FC. Postoperative acute pulmonary
oedema: a rare presentation of pheochromocytoma. Clin Nephrol 1997;
48:122-4. 
17. Hull CJ. Pheochromocytoma: diagnosis, preoperative preparation, and anaes-
thetic management. Br J Anaesth 1986; 58:1453-68.
18. Perel Y, Sclumberger M, Marguerite G, Alos N, Revillon y, Sommelet D, et al.
Pheochromocytoma and paraganglionoma in children: a report of 24 cases of
the French Society of Pediatric Oncology. Pediatr Hematol Oncol 1997;
14:413-22. 
19. Jalil ND, Pattou PN, Combemale F, Chafuis Y, Henry JF, Peix JL, et al.
Effectiveness and limits of preoperative imaging studies for localization of
pheochromocytomas and paragangliomas: a review of 282 cases. Eur J Surg
1998; 164:23-8. 
20. Serfas D, Shoback Dm, Lorell BH. Phaechromocytoma and hypertonic car-
diomyopathy: apparent suppression of symptoms and noradrenaline secretion
b calcium-chennel blockade. Lancet 1987;ii:711-3
21. Mardini MK. Echocardiographc findings in phaeochromocytoma. Chest
1981;3:394-6.
145 J Pak Med Assoc
Vol. 57, No. 3, March 2007 146
22. Emerson CE, Rainbird A. Use of a 'hospital-at-home' service for patient opti-
mization before resection of pheochromocytoma. Br J Anaesth 2003; 90:380-
82.
23. Bravo EL. Pheochromocytoma. Curr Ther Endocrinol Metab 1997; 6:195-97.  
24. Kinney MA, Warner ME, van Heerden JA, Horloiker TT, Young WF Jr,
Maxrun PM, et al. Perianesthetic risks and outcomes of Pheochromocytoma
and paraganglioma resection. Anesth Analg 2000; 91:1118-23.  
25. Sloand EM, Thompson BT. Propranolol- induced pulmonary edema and shock
in a patient with pheochromocytoma. Arch Intern Med 1984;144:173-4.
26. Shupak RC. Difficult anesthetic management during pheochromocytoma sur-
gery. J Clin Anesth 1999;11:247-250.
27. Proye C, Thevenin D, Cecat P, Petillot P, Carnaille B, Verin P, et al. Exclusive
use of calcium channel blockers in preoperative and intraoperative control of
pheochromocytomas: hemodynamics and free catecholamine assays in ten
consecutive patients. Surgery 1989; 106:1149-54.
28. Lee MK. Anaesthetic management for the removal of pheochromocytoma
with neurolept anaesthesia using high dose fentanyl - a case report. Singapore
Med J 1986; 27:158-62.
29. Bogdonof DI. Pheochromocytoma: specialist cases that all must be prepared
to treat. J Cardiothorasc Vasc Anesth 2002; 16:267-9.
30. Desmonts JM, Marty J. Anaesthetic management of patients with pheochro-
mocytoma. Br J Anaesth 1984; 56:781-9. 
31. Dugas G, Fuller J, Singh S, Watson J. Pheochromocytoma and pregnancy: a
case report and review of anesthetic management. Canadian Journal of
Anesthesia 2004; 51:134-8.
32. Ueda N. Kitamura Y, Takaki O, Hayashi Y, Uihida O, Kuro M, et al.
Anaesthetic management of pheochormocytoma associated with tricuspid
atresia. Can J Anaesth 1991; 38:780-4.
33. Zakowski M, Kaufman B, Berguson P, et al: Esmolol use during resection of
pheochromocytoma: Report of three cases. Anesthesiology 1989; 70:875-877.
34. James MFM. Use of magnesium sulphate in the anaesthetic management of
phaechromocytoma: a review of 17 anaesthetics. Br J Anaesth 1989; 62:616-23.
35. Channa Ab, Mofti AB, Taylor GW, Mekki MO, Sheikh MH. Hypoglycaemic
encephalopathy following surgery on phaeochromocytoma. Anaesthesia
1987; 42:1298-301.
